Aktienanalyse zu Aytu Biopharma Inc (AYTU)AYTUAytu Biopharma Inc

Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aytu Biopharma Inc is not a strong buy at this moment due to its current price of $1.85, which is significantly below its 52-week high of $3.06, indicating a potential for recovery but also substantial risk. The RSI is at 29.457, suggesting it is oversold, yet the company has faced a 33% year-over-year decline in net revenue for Q3, which raises concerns about its financial stability.

1 analysts cover AYTU: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.33.